Axsome Therapeutics, Inc. (AXSM) FY2025 10-K Annual Report
Axsome Therapeutics, Inc. (AXSM) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 23, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Axsome Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Development, commercialization, and sales of pharmaceutical products for CNS disorders, including AUVELITY, SUNOSI, and launch of SYMBRAVO in 2025
- • New product: Commercial launch of SYMBRAVO began June 2025, generating $6.6 million in net sales for the year, no sales in prior year
- • Strategic shift: Expanded commercial focus from AUVELITY and SUNOSI to include SYMBRAVO, increasing total revenues 65.6% YoY to $638.5 million in 2025
- • Quantitative metric: Net sales growth – AUVELITY sales up 74% to $507.1 million; SUNOSI up 33% to $120.1 million, total revenue increase from $385.7 million to $638.5 million
- • Noteworthy fact: Recorded a significant decrease in net loss, $183.2 million in 2025 vs $287.2 million in 2024, reflecting scaling commercialization efforts
Risk Factors
- • Regulatory risk: FDA Breakthrough Therapy designation for AXS-05 for AD agitation may not expedite approval or guarantee marketing authorization
- • Geopolitical risk: EU sanctions on Russia extended to July 31, 2026, with potential supply chain and capital market disruptions impacting operations
- • Supply chain risk: Dependence on third-party manufacturers subject to regulatory compliance and volume fulfillment could delay product commercialization
- • Market disruption risk: Competition from other pharma, biotech firms, government agencies, and research organizations may impair operating results
- • Financial risk: $570M Blackstone loan with restrictive covenants and minimum $30M liquidity may limit operational flexibility and risk default
Axsome Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$638M
▲ +65.5% YoY
Net Income
-$183M
▲ +36.2% YoY
Operating Margin
-26.1%
▲ +4662bp YoY
Net Margin
-28.7%
▲ +4578bp YoY
ROE
-207.5%
▲ +29630bp YoY
Total Assets
$690M
▲ +21.3% YoY
EPS (Diluted)
$-3.68
▲ +38.6% YoY
Operating Cash Flow
-$93M
▲ +27.3% YoY
Source: XBRL data from Axsome Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Axsome Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.